# Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

> **NCT02657889** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tesaro, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Neoplasms
- Triple Negative Breast Cancer
- Ovarian Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Stage IV Breast Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** niraparib
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT02657889
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-15
- **Primary completion:** 2018-05-14
- **Final completion:** 2021-09-17
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2022-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657889, "Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02657889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*